Cegedim Dendrite taps O'Rourke as consultant

Share this article:
Peg O'Rourke
Peg O'Rourke

Sales, marketing and compliance solutions consulting firm Cegedim Dendrite has hired one of the nation's foremost FDA regulations experts.

Margaret “Peg” O'Rourke, who spent a 35-year career at the FDA until her retirement earlier this year, has been named senior regulatory consultant for Cegedim Dendrite.

For the past 20 years, O'Rourke was responsible for enforcing the Prescription Drug Marketing Act (PDMA) amendments to the Federal Food, Drug, and Cosmetic Act.

PDMA amendments affect the distribution of prescription drug samples and the integrity of the national drug distribution system, including counterfeiting and the importation of prescription drugs into the US.

“Essentially I'm going to be doing the same thing for Cegedim Dendrite that I was doing for FDA, in the sense that I will be trying to assist the pharmaceutical industry in meeting the FDA regulations and statutes,” O'Rourke told MM&M. “It's a little different side of the coin but not totally. The whole point is to help the pharmaceutical manufacturers comply with the FDA rules and regulations.”

As part of Cegedim Dendrite O'Rourke will be responsible for third-party audits; sales force and home office training; mock FDA audits, general consultation and expert guidance regarding PDMA compliance issues.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.